Authors' reply

The Lancet

Volumn 381, Issue 9860, 2013, Pages 27-

  Wong, Conroy ^a   Jayaram, Lata ^a   Karalus, Noel ^b   Milne, David ^c   Tong, Cecilia ^d  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b Onash Medical Centre   (Australia)

^c WAIKATO HOSPITAL   (New Zealand)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL MYCOBACTERIUM; BRONCHIECTASIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; LETTER; NON CYSTIC FIBROSIS BRONCHIECTASIS; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; SCREENING; SPUTUM CULTURE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DISEASE EXACERBATION; MONOTHERAPY; MYCOBACTERIUM AVIUM COMPLEX; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIAE; FEMALE; MALE; NOTE;

AZITHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHIECTASIS; FEMALE; HUMANS; MALE;

EID: 84872760643     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/s0140-6736(13)60014-8     Document Type: Letter

References (2)

1. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-67.
2. Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 2005; 60: 1045-51.